Abstract:Enterotoxigenic Escherichia coli (ETEC) is one of the most common bacterial causes of diarrhea-associated morbidity and mortality, particularly among infants and young children in developing countries. Still, the true impact on child and traveler health is likely underestimated. There are currently no licensed vaccines for ETEC, but studies indicate high public health impact, cost-effectiveness, and feasibility of immune protection through vaccination. ETEC vaccine development remains a World Health Organization priority. Traditionally, ETEC vaccine development efforts have focused on inducing antitoxin and anticolonization antigen immunity, as studies indicate that antibodies against both antigen types can contribute to protection and thus have potential for vaccines. Leading cellular vaccine candidates are ETVAX (a mixture of four inactivated strains) and ACE527 (a mixture of three live attenuated strains), both of which have been found to be safe and immunogenic in Phase 1/2 trials. ETVAX is the furthest along in development with descending-age studies already underway in Bangladesh. Other ETEC vaccine candidates based on protein subunits, toxoids (both LT and ST), or novel, more broadly conserved ETEC antigens are also under development. Of these, a protein adhesin-based subunit approach is the most advanced. Impact and economic models suggest favorable vaccine cost-effectiveness, which may help expand market interest in ETEC vaccines. Combination vaccine formulations may help improve the economic case for development and use, and better point-of-care diagnostics will help to raise awareness of the true health burden of ETEC and highlight the potential public health benefit of ETEC vaccine introduction. Better diagnostics and vaccine demand forecasting will also improve vaccine development financing and support accelerated uptake once a licensed vaccine becomes available.

Future Vaccines Against Enteric Pathogens

Progress and Hurdles in the Development of Vaccines Against Enterotoxigenicescherichia Coliin Humans

Enteric infections and the vaccines to counter them: Future directions

Current Progress in Developing Subunit Vaccines Against Enterotoxigenic Escherichia Coli-Associated Diarrhea

Progress in enteric vaccine development

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects]

New vaccines against bacterial enteric infections

Vaccines against gastroenteritis, current progress and challenges

Vaccines against gastroenteritis, current progress and challenges (Reprinted from Gut Microbes, vol 11, pg 1486-1517, 2020)

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae

Vaccines and milk immunoglobulin concentrates for prevention of infectious diarrhea

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni

A review of the current status of enteric vaccines

Vaccines against cholera, typhoid fever and shigellosis for developing countries

Oral vaccination against enteric bacterial infections: An overview

Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli

Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine Development

[Advances in new vaccines against human enterotoxigenic Escherichia coli--A review]

Update on vaccines for enteric pathogens

Status of vaccine research and development for enterotoxigenic Escherichia coli

Vaccine development for enteric bacterial pathogens: Where do we stand?